Document Detail

Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis.
MedLine Citation:
PMID:  17474817     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Negative symptoms are among the most chronic symptoms of schizophrenia. Even with the advent of atypical antipsychotic drugs, negative symptoms remain mostly refractory to treatment. It has been proposed that selective serotonin reuptake inhibitor (SSRI) augmentation therapy in schizophrenia could provide a greater relief of these symptoms. Published studies, however promising, have produced conflicting results. OBJECTIVE: To overcome this discrepancy in results, we performed a meta-analysis of studies assessing SSRI add-on therapy for the negative symptoms of schizophrenia. DATA SOURCES AND STUDY SELECTION: A search was performed using the computerized search engines PsycINFO, PubMed (MEDLINE), and Current Contents. Keywords used were schizophrenia and (for SSRI) sertraline, citalopram, paroxetine, fluoxetine, and fluvoxamine. Hand search of published review articles as well as cross-referencing were carried out, too. Pharmaceutical companies were also contacted. Studies were retained if (1) SSRI add-on therapy was compared with antipsychotic monotherapy among schizophrenia-spectrum disorder patients; (2) the clinical trial was randomized, double-blind, placebo-controlled with parallel-arm design; (3) negative symptoms were assessed with the Scale for the Assessment of Negative Symptoms or the Positive and Negative Syndrome Scale-negative subscale. DATA EXTRACTION: With a consensus, authors (A.A.S. and S.P.) extracted and checked the data independently on the basis of predetermined exclusion and inclusion criteria. Effect size estimates were calculated using Comprehensive Meta-Analysis software. DATA SYNTHESIS: Eleven studies responded to our inclusion criteria. Within a random-effects model, a nonsignificant composite effect size estimate for (end point) negative symptoms was obtained (N = 393; adjusted Hedges' g = 0.178; p = .191). However, when studies were divided according to severity of illness, a moderate and significant effect size emerged for the studies involving so-called "chronic patients" (N = 274; adjusted Hedges' g = 0.386; p = .014). CONCLUSION: The current meta-analysis provides no global support for an improvement in negative symptoms with SSRI augmentation therapy in schizophrenia.
Amir Ali Sepehry; Stéphane Potvin; Robert Elie; Emmanuel Stip
Related Documents :
17110087 - The burden of depressive symptoms in the long-term treatment of patients with schizophr...
16199847 - Duration of untreated psychosis and time to treatment response for delusions and halluc...
11838627 - Vitamin b6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a...
10378227 - P300 and disability of daily life in schizophrenia.
19629797 - Internet treatment for social phobia reduces comorbidity.
11549407 - A double-blind placebo-controlled crossover study of phenytoin in individuals with impu...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of clinical psychiatry     Volume:  68     ISSN:  1555-2101     ISO Abbreviation:  J Clin Psychiatry     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-05-03     Completed Date:  2007-05-10     Revised Date:  2008-04-08    
Medline Journal Info:
Nlm Unique ID:  7801243     Medline TA:  J Clin Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  604-10     Citation Subset:  IM    
Fernand-Seguin Research Center, Louis-H Lafontaine Hospital, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Therapy, Combination
Randomized Controlled Trials as Topic
Schizophrenia / drug therapy*
Schizophrenic Psychology
Serotonin Uptake Inhibitors / therapeutic use*
Severity of Illness Index
Treatment Outcome
Reg. No./Substance:
0/Serotonin Uptake Inhibitors
Comment In:
J Clin Psychiatry. 2008 Jan;69(1):163-4   [PMID:  18312053 ]
Evid Based Ment Health. 2007 Nov;10(4):113   [PMID:  17962663 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia.
Next Document:  A high-density whole-genome association study reveals that APOE is the major susceptibility gene for...